Sun Pharma Advanced Research Company Issues Corrigendum to EGM Notice Following NSE Observations

2 min read | Published on 29 Jan 2026, 07:48 PM |Updated on 29 Jan 2026, 07:48 PM

Reviewed by

Suketu GScanX News Team

Key Highlights

Sun Pharma Advanced Research Company Limited issued a corrigendum on January 29, 2026, to its EGM notice dated January 14, 2026, following observations from NSE. The corrigendum provides additional clarity on shareholding patterns, showing promoter holding at 65.67% pre-issue and 69.31% post-allotment. The EGM is scheduled for February 9, 2026 at 4:00 p.m. via video conferencing, with no changes to the proposed warrants issue structure.

*this image is generated using AI for illustrative purposes only.

Sun pharma advanced research co has issued a corrigendum dated January 29, 2026, to its Extra-Ordinary General Meeting (EGM) notice, addressing observations from the National Stock Exchange of India Limited and providing additional clarity to shareholders ahead of the scheduled meeting.

EGM Details and Regulatory Compliance

The corrigendum pertains to the EGM notice originally dated January 14, 2026, which was dispatched on January 16, 2026. The company received observations from NSE through their letter dated January 27, 2026, pursuant to the In-Principle Approval Application filed by the company. The EGM is scheduled for Monday, February 9, 2026 at 4:00 p.m. (IST) through Video Conferencing and Other Audio-Visual Means.

The corrigendum forms an integral part of the original EGM notice and must be read in conjunction with it. All other contents of the EGM notice remain unchanged except for the modifications and supplements provided in the corrigendum.

Shareholding Pattern Clarification

The corrigendum provides detailed clarification on the company's equity share capital structure, specifically addressing Paragraph 5 of Item No. 1 of the Explanatory Statement. The shareholding pattern is presented with data as of January 14, 2026:

Category	Pre-issue Shares	Pre-issue %	Post-Allotment Shares	Post-Allotment %
Promoter & Promoter Group	21,31,15,095	65.67%	25,16,25,095	69.31%
Indian Individuals/HUF	6,54,40,885	20.17%	6,54,40,885	18.03%
Bodies Corporate	13,72,17,968	42.28%	17,57,27,968	48.40%
Person Acting in Concert	1,03,01,320	3.17%	1,03,01,320	2.84%
Public Shareholding	11,14,06,493	34.33%	11,14,06,493	30.69%
Total	32,45,21,588	100.00%	36,30,31,588	100.00%

Capital Structure Details

The company has provided comprehensive details about its share capital structure based on the Reconciliation of Share Capital Audit filed for the December 2025 quarter:

Parameter	Number of Shares
Issued Capital	32,45,34,125
Listed Capital	32,44,99,774
Paid-up Capital	32,45,21,588

The differences between these figures are attributed to specific historical events, including shares kept under abeyance from the May 5, 2007 allotment and share forfeitures that occurred on July 24, 2015.

Publication and Dissemination

The corrigendum will be published in Financial Express (English) and Financial Express Ahmedabad Edition (Gujarati) on January 30, 2026. It will also be made available on the websites of BSE Limited and National Stock Exchange of India Limited, as well as on the company's website. The document will be circulated to members through electronic means to ensure adequate dissemination before e-voting commences.

The company has confirmed that there is no change to the proposed size, pricing, or structure of the Warrants Issue mentioned in the original EGM notice. The post-issue shareholding pattern assumes full conversion of all warrants into equivalent equity shares.

Historical Stock Returns for Sun Pharma Advanced Research Co